FDA Approves Expanded Use Of Roche's Influenza Treatment

by Vandana Singh, Benzinga Editor

August 12, 2022 11:21 AM | 1 min read |

The FDA has approved the expanded use of Roche Holding AG's RHHBY Xofluza (baloxavir marboxil).
The medicine has been approved to treat acute uncomplicated influenza in otherwise healthy children aged 5-12 years who have shown symptoms for no more than 48 hours.
This marks the first single-dose oral influenza medicine approved in the US for children in this age group.
The FDA also approved Xofluza to prevent influenza in children aged five years to less than 12 years following contact with an infected person.
Roche said Xofluza is already FDA-approved to treat influenza in people aged 12 and above.
Price Action: RHHBY shares are up 1.71% at $41.74 during the market session on the last check Friday.

Posted In:

Biotech Large Cap News Health Care FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.